Post-operative residual disease and number of cycles of neoadjuvant chemotherapy in advanced epithelial ovarian carcinoma.

ABSTRACT:

Background

The optimal number of neoadjuvant chemotherapy cycles in patients with advanced ovarian cancer is still disputed.

Objective

To evaluate the impact of the number of neoadjuvant chemotherapy cycles and role of optimal cytoreduction on the prognosis of patients with advanced ovarian cancer.

Methods

Clinical and pathological details were examined. Patients were evaluated combining the number of cycles of neoadjuvant chemotherapy-namely, 'interval debulking surgery' after up to four neoadjuvant chemotherapy cycles, and 'delayed debulking surgery' after more than four cycles of therapy.

Results

A total of 286 patients were included in the study. Complete cytoreduction with no residual peritoneal disease (CC0) was achieved in 74 (74%) patients with interval

SUBMITTER: Perrone AM 

PROVIDER: S-EPMC10423511 | biostudies-literature | 2023 Aug

REPOSITORIES: biostudies-literature